IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
Luo, Feng Roger1,2; Ding, Jian3; Chen, Helen X.1,4; Liu, Hao5; Fung, Man-Cheong2; Koehler, Maria6; Armand, Jean Pierre7; Jiang, Lei3; Xu, Xiao1,8; Zhang, Ge9; Xu, Li1,9; Qian, Pascal1,5; Yan, Li1,10
关键词Breakthrough Clinical Trial Cancer Medicine
刊名CHINESE JOURNAL OF CANCER
2014-12-01
DOI10.5732/cjc.014.10246
33期:12页:620-624
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]CELL LUNG-CANCER ; GASTRIC-CANCER ; BREAST-CANCER ; INHIBITOR ; PCI-32765 ; IBRUTINIB
英文摘要

The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the 17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China.

语种英语
WOS记录号WOS:000346228500007
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54669
专题北京大学临床肿瘤学院
作者单位1.US Chinese Anticanc Assoc, Martinez, CA 94553 USA
2.Novartis Pharmaceut China Oncol, Beijing 10004, Peoples R China
3.Pfizer Oncol, New York, NY 10017 USA
4.Inst Gustave Roussy, F-94805 Villejuif, France
5.ACEA Biosci Inc, San Diego, CA 92121 USA
6.Jiangsu Hengrui Med Co Ltd, Shanghai 200122, Peoples R China
7.Janssen Res & Dev LLC, Dept Oncol, Raritan, NJ 08869 USA
8.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
9.NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
10.Peking Univ, Beijing Canc Hosp & Inst, Sch Oncol, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Luo, Feng Roger,Ding, Jian,Chen, Helen X.,et al. Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting[J]. CHINESE JOURNAL OF CANCER,2014,33(12):620-624.
APA Luo, Feng Roger.,Ding, Jian.,Chen, Helen X..,Liu, Hao.,Fung, Man-Cheong.,...&Yan, Li.(2014).Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.CHINESE JOURNAL OF CANCER,33(12),620-624.
MLA Luo, Feng Roger,et al."Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting".CHINESE JOURNAL OF CANCER 33.12(2014):620-624.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Luo, Feng Roger]的文章
[Ding, Jian]的文章
[Chen, Helen X.]的文章
百度学术
百度学术中相似的文章
[Luo, Feng Roger]的文章
[Ding, Jian]的文章
[Chen, Helen X.]的文章
必应学术
必应学术中相似的文章
[Luo, Feng Roger]的文章
[Ding, Jian]的文章
[Chen, Helen X.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。